USC researchers have identified drug compounds that could reduce brain inflammation in Alzheimer's disease by targeting cPLA2, an enzyme that triggers harmful neuroinflammation while maintaining normal brain function.
The team focused on people carrying the APOE4 gene, which substantially increases Alzheimer's risk. The researchers discovered that cPLA2 (cytosolic phospholipase A2) drives pathological inflammation in these individuals. The compounds they developed selectively inhibit cPLA2 activity tied to inflammation without disrupting the enzyme's essential roles in neurons.
This distinction matters because cPLA2 performs critical functions in healthy brains, including cell signaling and membrane repair. Blocking it entirely would damage normal brain activity. The USC team engineered compounds that suppress only the inflammatory pathway, preserving beneficial functions.
Alzheimer's disease involves multiple mechanisms, including accumulation of amyloid-beta and tau proteins, but neuroinflammation significantly accelerates cognitive decline. Microglia, brain immune cells, become hyperactivated and release inflammatory molecules that damage neurons. The APOE4 gene variant makes this inflammation response worse.
The research suggests a new therapeutic angle beyond current approaches. Existing Alzheimer's drugs primarily target amyloid-beta plaques, with limited success in slowing disease progression. Anti-inflammatory strategies targeting cPLA2 could complement these treatments or work independently.
The compound specificity represents a technical advance. Previous cPLA2 inhibitors failed clinically because they were too broad, blocking both inflammatory and protective functions simultaneously. The USC compounds achieve selectivity by distinguishing between different downstream pathways the enzyme activates.
Next steps include testing these compounds in preclinical models and determining appropriate dosing and delivery to the brain. The work remains in early stages, and human trials remain distant. However, the identification of cPLA2